Cyclin helix B peptide (CHBP)-based therapy for body weight control, energy homeostasis and TIIDM: Cyclin helix B peptide (CHBP),  derived from Erythropoietin (EPO)/Hematopoietin, inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 26/April/2019, 10.55 pm